Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04387461
Title Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (Core-001)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors CG Oncology, Inc.
Indications

urinary bladder cancer

Therapies

CG0070 + Dodecyl Maltoside + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.